We are pleased to present the 2022 BostonSight Annual Report and financials.  The report begins with a Letter from our President and CEO and Board Chair, followed by updates on Education, Global Access and Manufacturing, and Research.  You will also find a list of our generous donors, without whom we would be unable to provide our many services to patients.  We thank you.

Letter from the President and CEO, Sara Yost, and Board Chair, David Rosenbloom:

“It is with great pleasure that we present the 2022 Annual Report for BostonSight. Over the past year, we have continued to make significant progress in delivering on our mission of providing innovative, high-quality treatment, impactful clinical research, eye-opening education, and advanced scleral lens technology to patients around the world.

Since 1992, we have seen the life-changing impact PROSE treatment and scleral lenses provide. Each day we are grateful to share in the joy from patients and their families as pain is diminished and sight is restored. As we have grown, we have been steadfast in keeping the patient at the core of our organization – not only the patients in our Needham Clinic, but also the patients in PROSE Provider Network sites, and BostonSight SCLERAL practitioner offices down the road or halfway around the globe.

Our experience with patients fuels our commitment to playing a significant role in the global adoption of scleral lenses. We continue to search for ways to bring hope to patients who do not yet know about the life-changing treatment of scleral lenses or who are in areas of the world where access to scleral lens technology is limited.

In 2022, we saw significant growth in our reach to patients. In the United States and Canada, we added 74 optometry practices to the BostonSight SCLERAL network, bringing the total to over 400 practices in North America. Our partners in Latin America and India saw major growth in patient access and expanded reach to new countries. To broaden availability around the world, we entered into an agreement… Continue reading